Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Hepatitis C: KOL Insight and Consensus Outlook

Product Code:
596200245
Publication Date:
December 2013
Latest Update Bulletin:
January 2015
Format:
PDF + Excel
Pages:
163 + Data File
Price:
£5,230

Approval of Gilead’s once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in class therapy represents a paradigm shift compared to the protease inhibitors and interferon regimens. With convenient, efficacious and safer therapies coming through the pipeline – led by Gilead, AbbVie and Bristol-Myers Squibb – the battle to transform this potentially lucrative market will be intense.

Therapy Trends: Hepatitis C is compiled from exclusive, in-depth interviews with the world’s leading KOLs in HCV. It identifies and analyses the major factors, advances and trends currently influencing the HCV treatment landscape. The report focuses on late-stage pipeline products and existing marketed therapies, providing strategic insights which key industry decision makers use to answer critical business questions.

FirstWord selected KOLs for this report based on their level of engagement and influence within the HCV pharmaceutical industry, and on their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how HCV clinical research will shape the future market.

Key Benefits

This report includes access to regular updates. The most recent update bulletin covers Janssen-Cilag/Medivir, Olysio, Gilead, sofosbuvir, ledipasvir, AbbVie, 3D combination, access to new HCV therapies.

 Therapy Trends: Hepatitis C -- Game changing regimens to revolutionise treatment landscape examines the most prominent insights gained from the field’s key opinion leaders. The results of FirstWord’s research and analysis will help you to:

  • Comprehend the current trends driving and shaping the global HCV market
  • Understand the future landscape and how new classes will fit into the treatment algorithm
  • Assess the commercial and clinical potential of the pipeline nucs, non-nucs, NS5A inhibitors and next generation protease inhibitors
  • Develop planning strategies based on KOL insight
  • Identify the unmet needs and opportunities for disease management
  • Evaluate the performance of companies with the most robust new product pipelines
  • Recognise the key factors KOLs predict will drive future treatment trends

The hepatitis C (HCV) market is expected to become one of the fastest growing markets in Pharma over the next decade given a sizable 170 million patient population, a significant unmet need and rapid advancements in the clinic. The management of this infectious disease is on the edge of a revolution that will bring considerable changes to the treatment algorithm. KOLs from North America and Europe provide answers to some critical questions regarding the global HCV market, including:

  • What do KOLs make of the Sovaldi and Olysio and their impact on treatment?
  • What are the current unmet needs and major challenges in HCV treatment?
  • What are the most promising late-stage classes in development?
  • Which therapies are KOLs eagerly awaiting?
  • How will the nucleotide inhibitors, non-nucs, and NS5A inhibitors be positioned in the HCV market?
  • How do the second generation protease inhibitors differ from their first-generation cousins?
  • In what ways could eventual biomarkers improve future HCV disease management?
  • How will treatment of HCV look in the future?
  • How do KOLs think the pricing of new direct-acting antivirals will shape the uptake of new HCV treatments?
  • What clinical research trends do KOLs predict for future HCV therapies?

Hepatitis C’s Panel of Key Opinion Leaders

FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the HCV pharmaceutical industry, and their scientific standing. The HCV KOL panel assembled for this Therapy Trends research is drawn from North America and Europe professionals:

  • Adult Viral Hepatitis Prevention Coordinator, Bureau of Epidemiology, Pennsylvania Department of Health, Harrisburg, PA, USA
  • Director of Hepatology, Medicine Service, Massachusetts General Hospital, MA, USA
  • President and Medical Director at Alamo Medical Research, Texas, USA
  • Head, Division of Gastroenterology and Hepatology, Scripps Clinic, CA, USA
  • Chief Medical Officer at Alamo Medical Research Texas, USA
  • Head of the Liver Institute of Virginia, Virginia, USA
  • Department of Hépato-Gastroenterologie, Centre Hospitalier Universitaire de Nancy-Brabois, Vandoeuvre-lès-Nancy, France
  • Professor of Medicine at the University of Vienna, Vienna General Hospital, Wien, Austria
  • Professor at Hôpital Saint Eloi, Montpellier, France
  • Co-lead of HCV Research UK, MRC Virology Unit, Glasgow, Scotland
  • Professor of Medicine and Chief of the Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany

To purchase this module individually, please click here.

Hepatitis C - Consensus Outlook

Click here for sample pages

Therapy Trends Consensus Outlook: Hepatitis C provides an in-depth analysis of the products players and events that will shape the future HCV market.

Therapy Trends Consensus Outlook: HIV includes the following comprehensive resources:

  • An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance
  • An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
  • Updated reports and data analysis files delivered to your inbox after each significant market event.

Key Benefits

Therapy Trends Consensus Outlook: Hepatitis C provides:

  • Evaluate future sales forecasts and predicted market growth
  • Map your market parameters and chart commercial prospects
  • Assess market share by company and product
  • Tailor your strategic and investment focus based on the competition
  • Set proactive launch and branding strategies
  • Keep up with event-driven market data updates

Forecast analysis report and data model

The forecast analysis report component of Consensus Outlook: Hepatitis C delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.  

  • Historical HCV sales from 2007–2012
  • Forecast HCV sales from 2013-2017
  • Key competitors and drug developers
  • Predicted product positioning
  • Current and late-stage pipeline drugs
  • Future event mapping to forecast data points
  • Comparative clinical trial results

FirstWord’s HCV forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.

  • Market size
  • Product sales
  • Company forecasts
  • Company, brand, and drug class
  • Mechanism of action Future events

 

To purchase this module individually, please click here.

Content Highlights

Click here for sample pages

Hepatitis C - KOL Insight

Current Hepatitis C marketplace

  • Hepatitis C overview
  • Current treatment landscape
  • Reimbursement of key Hepatitis C brands
  • Unmet needs in Hepatitis C

Current therapies

  • NS5B nucleoside (Nuc) inhibitors overview
    • Sovaldi (sofosbuvir; Gilead Sciences) trends
  • NS3/NS4A Protease inhibitor overview
    • Olysio (simeprevir; Medivir/Janssen) trends
    • Incivek/Incivo (telaprevir; Vertex's/ Janssen/Mitsubishi Tanabe) trends
    • Victrelis (boceprevir; Merck) trends
  • Interferon and Ribavirin Overview
    • Pegylated interferon-alpha (Peg-Intron, PegaSys) and ribavirin trends
  • Current treatment algorithm

Future Hepatitis C marketplace

  • Future treatment landscape
  • NS5B nucleoside (Nuc) inhibitors overview
    • Mericitabine (RO5024048; Roche/Gilead) trends
  • NS5B non-nucleoside inhibitor overview
    • ABT-333 (AbbVie) trends
    • ABT-072 (AbbVie) trends
    • VX-222 (Vertex) trends
    • Tegobuvir (GS-9190; Gilead) trends
  • NS5A replication complex inhibitor overview
    • Daclatasvir (BMS-790052; Bristol-Myers Squibb) trends
    • GS-5885 (Gilead Sciences) trends
    • ABT-267 (AbbVie) trends
    • ACH-3102 (Achillion) trends
  • NS3/NS4A protease inhibitor overview
    • Faldaprevir (BI-201335; Boehringer Ingelheim) trends
    • ABT-450 (AbbVie/Enanta) trends
    • Asunaprevir (BMS-650032; Bristol-Myers Squibb) trends
    • Danoprevir (RO5190591; Roche) trends
    • Sovaprevir (ACH-1625; Achillion Pharmaceuticals) trends
    • MK-5172 (Merck) trends Vaniprevir (MK-7009; Merck) trends
  • Future treatment algorithm

Future developments in Hepatitis C

  • Education to raise awareness and improve diagnosis
  • Clinical trials will evolve in the future
  • Constrained pricing environments will reduce market access
  • Effective shorter treatment regimes will emerge
  • biomarkers will be useful but not essential

Hepatitis C - Consensus Outlook

  • Hepatitis C Marketplace
  • Key Hepatitis C Developers
  • Hepatitis C Class Dynamics
  • Sovaldi (sofosbuvir (GS-7977, Gilead) forecast
  • Olysio (simeprevir; Medivir/Tibotec) forecast
  • Incivek (telaprevir; Vertex Tibotec/Mitsubishi Tanabe) forecast
  • Victrelis (boceprevir; Merck) forecast
  • PegaSys (pegylated interferon-alpha; Roche) forecast
  • PegIntron (pegylated interferon-alpha; Merck) forecast
  • Abbott franchise (ABT-333/ABT-450/ABT-267; Abbott) forecast
  • Bristol-Myers Squibb franchise (daclastasvir/asunaprevir) forecast
  • Sovaprevir (ACH-1625; Achillion Pharmaceuticals) forecast
  • MK-5172 (Merck) forecast
  • Vaniprevir (MK-7009; Merck) forecast
  • VX-222 (Vertex) forecast

Ongoing Benefits

Click here for sample pages

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with regular update bulletins offers a real commercial advantage.

Consider the benefits:

  • Regular updates to cover significant market events such as new product approvals or pivotal research results will be covered with primary market research with preeminent KOLs
  • Each update bulletin provides Therapy Trends clients with fresh expert insights on the likely impact of the latest market developments
  • Therapy Trends clients get access to the results of primary research through Research Update Bulletins – brief reports that bring the impact of the latest events into sharp focus
  • All updates are included in the price.



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved